1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,070 | 1,074 | 22:15 | |
| 1,070 | 1,074 | 17:39 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.01. | CARMAT Announces Its Participation in Several Scientific and Investor Conferences During the 1st Half of 2025 | 245 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
| 08.01. | CARMAT Delivers a Solid FY 2024 with 42 Implants of Its Aeson Artificial Heart and Anticipates Continued Strong Momentum in 2025 | 243 | Business Wire | Over 90 patients have received the Aeson® artificial heart since the first implant in 2013, including 42 in 2024.
2024 Sales of €7 million (a 2.5-fold increase vs 2023).
Cash burn... ► Artikel lesen | |
| 23.12.24 | CARMAT optimizes its financial structure by buying-back, for a symbolic sum of one euro, 2 million shares from Matra-Défense (Airbus group) which will be allocated to the repayment of its financial debt | 377 | Business Wire | Buy-back by CARMAT of 2 million shares from Airbus for a symbolic sum of 1 euro. The shares so bought-back will be allocated to the repayment of the Company's financial debt, via their... ► Artikel lesen | |
| 26.11.24 | Successful first "Aeson European User Meeting", marking an important step in the deployment of CARMAT's artificial heart | 110 | Business Wire | More than 100 healthcare professionals from 41 hospitals and 10 countries rallied to share their experiences of the Aeson® artificial heart All hospitals taking part in the event confirmed... ► Artikel lesen | |
| 13.11.24 | CARMAT's Aeson Artificial Heart Is Gradually Becoming a Reference Solution for Bridge to Transplant in Europe | 562 | Business Wire | Milestone of 30 heart transplants post Aeson® support, passed Strong interest in Aeson® from the medical community: more than 100 European experts will share their experience at the first... ► Artikel lesen | |
| CARMAT Aktie jetzt für 0€ handeln | |||||
| 30.09.24 | CARMAT Announces the Completion of Its Capital Increase for a Gross Amount of €10.3 Million (Namely 100% of the Initial Offer) | 410 | Business Wire | Continued and significant support from two reference shareholders, for a total amount of €5.5 million Net proceeds of €9.4 million, enabling CARMAT to extend its cash runway until early... ► Artikel lesen | |
| 18.09.24 | CARMAT Launches a Capital Increase for an Initial Amount of €10.3 Million to Finance Its Activities Until at Least the End of 2024 | 495 | Business Wire | This capital increase will be carried out through a public offering without preferential subscription rights and with a 7 trading days priority period, on an irreducible and reducible basis,... ► Artikel lesen | |
| 12.09.24 | Half of Enrolments Targeted in the EFICAS Study Reached by CARMAT | 394 | Business Wire | Enrolment expected to be completed in the first half of 2025
Publication of study results on 52 patients anticipated at the end 2025
Regulatory News:
CARMAT (FR0010907956, ALCAR)... ► Artikel lesen | |
| 06.09.24 | CARMAT Publishes Its 2024 Half-Year Results and Provides an Update on Its Outlook | 527 | Business Wire | Half-year sales of €3.3 million, exceeding 2023 full-year sales
20 implants of the Aeson® artificial heart performed in the first half of 2024
17% cash-burn1 reduction compared to... ► Artikel lesen | |
| 03.09.24 | CARMAT Announces Its Participation in Several Scientific and Investor Conferences during the 2nd Half of 2024 | 459 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
| 09.07.24 | CARMAT accelerates its sales momentum and reiterates its confidence in its development outlook | 493 | Business Wire | 20 implants of the Aeson artificial heart performed in the first half of 2024
Pace of 4 implants per month in the second quarter
Half-year sales at €3.2 million, higher than the... ► Artikel lesen | |
| 08.07.24 | CARMAT to Provide a Half-Year Update on July 9, 2024 | 421 | Business Wire | Videoconference in French on July 9, 2024 at 6:00 pm CEST.
To participate, please register by clicking on this link
Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of... ► Artikel lesen | |
| 05.07.24 | CARMAT Secures an Equity Financing Line With Vester Finance | 615 | Business Wire | Flexible financing of up to 3,500,000 shares over 24 months CARMAT to receive immediately €2.2 million under this financing, thus extending the Company's cash runway until the end of September... ► Artikel lesen | |
| 25.06.24 | CARMAT Announces Updates in Its Governance | 557 | Business Wire | Appointment of Mr. Pierre Bastid as Chairman of the Board of Directors to succeed Mr. Alexandre Conroy, who has resigned for personal reasons Retirement of Mr. André Muller, independent... ► Artikel lesen | |
| 13.06.24 | CARMAT Announces the Start of the Equitization of the First Tranche of Its EIB Loan | 378 | Business Wire | Equitization of the first tranche of the EIB loan will reduce its repayment in cash and optimize the Company's cash position Set-up of a trust and issuance of share warrants to the trustee... ► Artikel lesen | |
| 30.05.24 | CARMAT Announces the Approval of All Resolutions Supported by the Board of Directors at Its Annual General Meeting | 304 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
| 17.05.24 | CARMAT Successfully Raises a Total of €16.0 Million | 695 | Business Wire | Regulatory News:
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, SOUTH AFRICA, CANADA, AUSTRALIA OR JAPAN
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced... ► Artikel lesen | |
| 16.05.24 | CARMAT Launches a Global Offering of Around €15 Million, With Subscription Commitments Totalling €8 Million | 476 | Business Wire | Global offering composed of a reserved offering for specialized investors and a public offering for retail investors via the PrimaryBid platform
Issue price of new shares of €3.00 per share... ► Artikel lesen | |
| 06.05.24 | CARMAT Continues to Build on Its Momentum in the EFICAS Study and Reiterates Confidence in Its 2024 Outlook | 373 | Business Wire | EFICAS study reaches the milestone of 20 implants
Interim study results above expectations
Confirmation of short-term financial support from several key shareholders
Regulatory... ► Artikel lesen | |
| 30.04.24 | CARMAT: Availability of the 2023 Universal Registration Document | 323 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen |
Seite:
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 36,720 | -0,22 % | Leichte Zugewinne bei der Fresenius SE & Co. KGaA-Aktie (36,58 €) | Das Wertpapier von Fresenius SE & Co. KGaA notiert heute fester. Der jüngste Kurs betrug 36,58 Euro. Die Fresenius+Co KgaA-Aktie verzeichnet gegenwärtig einen Wertanstieg von 2,75 Prozent. Sie hat sich... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 46,650 | +0,09 % | GOLDMAN SACHS stuft FMC FRESENIUS MEDICAL CARE AG & CO KGAA auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat die Einstufung für FMC mit einem Kursziel von 52 Euro auf "Buy" belassen. Analyst Richard Felton nahm in einer am Montagabend vorliegenden... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 53,48 | -1,58 % | UBS stuft Siemens Healthineers auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Siemens Healthineers mit einem Kursziel von 53 Euro auf "Neutral" belassen. Im europäischen Medizintechnik-Bereich gebe... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 56,30 | +6,03 % | JPMORGAN stuft CARL ZEISS MEDITEC AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Carl Zeiss Meditec mit einem Kursziel von 40 Euro auf "Underweight" belassen. Das erste Geschäftsquartal dürfte mau ausfallen... ► Artikel lesen | |
| ECKERT & ZIEGLER | 53,30 | +5,96 % | AKTIONÄR-Tipp Telix Pharma: Zulassung - darum profitiert auch Eckert & Ziegler | In den USA wird das radiopharmazeutische Diagnostik-Produkt Illuccix bereits regelrecht aus den Regalen gerissen. Entwickler Telix Pharma kann den Top-Seller nun auch in Europa auf den Markt bringen.... ► Artikel lesen | |
| DRAEGERWERK | 56,00 | +0,18 % | Drägerwerk-Vorzugsaktie: Wie nachhaltig ist der Kursanstieg? | Die Drägerwerk-Vorzugsaktie befindet sich seit Dezember in einem starken Aufwärtstrend. Auch am Freitag verbessert sie sich um +4,1% auf aktuell 55 €. Was ist hier zu erwarten und lohnt sich ein Einstieg?... ► Artikel lesen | |
| MEDTRONIC | 85,90 | +0,22 % | Medtronic Appoints Thierry Pieton As CFO | WASHINGTON (dpa-AFX) - Medtronic Plc (MDT), a healthcare technology company, said on Tuesday that it has appointed Thierry Pieton as its Chief Financial Officer with effect from March 3. Pieton... ► Artikel lesen | |
| INTUITIVE SURGICAL | 557,50 | -4,49 % | Soll ich diese Aktien jetzt kaufen? Intel, Intuitive Surgical und UnitedHealth im Check | Soll ich diese Aktien jetzt kaufen? Intel, Intuitive Surgical und UnitedHealth im Chec ► Artikel lesen | |
| GERRESHEIMER | 64,85 | +1,25 % | EQS-PVR: Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Gerresheimer AG
Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of... ► Artikel lesen | |
| UNITEDHEALTH | 507,60 | -0,16 % | DAX: Fällt der nächste Rekord? Außerdem: Aktien von Qiagen und UnitedHealth im Fokus | Der DAX hat am Freitag den dritten Rekordtag in Folge verbucht. Kurz vor dem Amtsantritt von Donald Trump als US-Präsident stieg der Leitindex im frühen Handel erstmals über die Marke von 20.700 Punkten.... ► Artikel lesen | |
| TELADOC HEALTH | 9,700 | -0,30 % | Amazon Adds Teladoc Health to Health Benefits Program | ||
| THERMO FISHER | 549,50 | -0,40 % | Is Thermo Fisher Stock Worth Holding on to in Your Portfolio? | ||
| STRATEC | 33,300 | -1,19 % | Stratec-Aktie: Kurs legt zu (34,90 €) | Im Plus liegt derzeit das Wertpapier von Stratec . Das Papier notiert gegenwärtig bei 34,90 Euro. An der deutschen Börse hat sich heute der Anteilsschein von Stratec zwischenzeitlich um 2,65 Prozent... ► Artikel lesen | |
| RHOEN-KLINIKUM | 14,500 | -2,03 % | Präzision in der Neurochirurgie: Roboterarm erstmals bei Wirbelsäulenoperation am RHÖN-KLINKUM Campus Bad Neustadt erfolgreich eingesetzt | Bad Neustadt a.d. Saale (ots) - In der Klinik für Neurochirurgie am RHÖN-KLINIKUM Campus Bad Neustadt wurde erstmals eine Wirbelsäulenoperation mit einem innovativen Roboterarm durchgeführt. Die neue... ► Artikel lesen | |
| ALLURION TECHNOLOGIES | 8,430 | +165,93 % | Pre-market Movers: Allurion Technologies, Nvni Group, Dogwood Therapeutics, Jupiter Neurosciences, Ctrl Group | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.15 A.M. ET).In the Green Allurion Technologies Inc. (ALUR) is up over 297%... ► Artikel lesen |
Das Unternehmen CARMAT kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,92 % bei einem Aktienkurs von 1,074 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CARMAT finden Sie auf Wallstreet Online.
